Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Commvault Systems Inc (CVLT) vs Cassava Sciences Inc (FLNA) Price & Performance

Commvault Systems IncTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

Commvault Systems Inc vs Cassava Sciences Inc — how do they compare? Commvault Systems Inc trades at $139.62 (market cap $5.78B), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Commvault Systems Inc is far larger — about 121× Cassava Sciences Inc's market cap, and Commvault Systems Inc is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

CVLTFLNA
Market Cap
$5.78B$47.75M
Sector
TechnologyHealth
52-Week High
$195.41$4.64
52-Week Low
$75.18$0.87
Enterprise Value
$5.77B-$34.93M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Commvault Systems Inc

Commvault Systems (CVLT) trades at $135.27, up 1.43% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows robust profitability with an 81.09% gross margin and 32.77% ROE, though valuation multiples like a P/E of 89.38 are elevated. Recent news highlights growth in SaaS revenue and new security integrations, such as the Threat Scan partnership with Google, driving positive analyst sentiment.

The outlook remains positive with a consensus price target of $172.40, implying 27% upside, supported by subscription growth and cash flow improvements. Risks include high valuation sensitivity, competitive pressures in data security, and fiduciary duty investigations noted in recent legal alerts, which could impact investor confidence near-term.

Cassava Sciences Inc

FLNA trades at $0.995, up 3.75% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported three consecutive quarterly earnings beats, with Q2 2026 EPS of -$0.18 beating expectations of -$0.225. Financials show negative cash flows and profitability, with ROE at -55.79% and net income of -$90.97M in 2025. Analyst consensus is strongly positive with 8 buy ratings out of 12.

Despite operational losses, FLNA's consistent earnings beats and strong analyst support suggest potential upside if clinical developments progress. Key risks include sustained cash burn, lack of revenue, and dependence on successful drug trials for Tuberous Sclerosis Complex. The stock remains speculative with high volatility expected.

Returns comparison

Trailing returns across standard periods

About Commvault Systems Inc

Commvault provides enterprise-grade data protection and information management software. Its platform helps businesses manage, back up, and recover data across on-premises, cloud, and hybrid environments.

Read more on CVLT

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA